jskn033
mAbexperimentalBi-specific
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 18, 2024 (NCT06226766)
Timeline
Indications
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07283198 | Phase 2 | Dec 10, 2025 | Alphamab Co., Ltd. |
| NCT06770881 | Phase 1/Phase 2 (Phase 2) | Jan 15, 2025 | Alphamab Co., Ltd., Fudan University |
| NCT06226766 | Phase 1/Phase 2 (Phase 2) | Jan 18, 2024 | Alphamab Co., Ltd., Scientia Clinical Research Limited Sydney |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alphamab Co., Ltd. | For profit | 3 | 3 | 1 | 2024 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Scientia Clinical Research Limited Sydney | For profit | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1